Abstract
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Blood |
| Vol/bind | 114 |
| Udgave nummer | 26 |
| Sider (fra-til) | 5271-8 |
| Antal sider | 8 |
| ISSN | 0006-4971 |
| DOI | |
| Status | Udgivet - 2009 |
Bibliografisk note
Keywords: Adolescent; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Genes, abl; Humans; Kaplan-Meiers Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Young AdultAdgang til dokumentet
Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
I: Blood, Bind 114, Nr. 26, 2009, s. 5271-8.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
}
TY - JOUR
T1 - Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation
AU - Nicolini, Franck E
AU - Mauro, Michael J
AU - Martinelli, Giovanni
AU - Kim, Dong-Wook
AU - Soverini, Simona
AU - Müller, Martin C
AU - Hochhaus, Andreas
AU - Cortes, Jorge
AU - Chuah, Charles
AU - Dufva, Inge H
AU - Apperley, Jane F
AU - Yagasaki, Fumiharu
AU - Pearson, Jay D
AU - Peter, Senaka
AU - Sanz Rodriguez, Cesar
AU - Preudhomme, Claude
AU - Giles, Francis
AU - Goldman, John M
AU - Zhou, Wei
N1 - Keywords: Adolescent; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Genes, abl; Humans; Kaplan-Meiers Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Young Adult
PY - 2009
Y1 - 2009
N2 - The BCR-ABL T315I mutation represents a major mechanism of resistance to tyrosine kinase inhibitors (TKIs). The objectives of this retrospective observational study were to estimate overall and progression-free survival for chronic myeloid leukemia in chronic-phase (CP), accelerated-phase (AP), or blastic-phase (BP) and Philadelphia chromosome-positive (Ph)(+) acute lymphoblastic leukemia (ALL) patients with T315I mutation. Medical records of 222 patients from 9 countries were reviewed; data were analyzed using log-rank tests and Cox proportional hazard models. Median age at T315I mutation detection was 54 years; 57% cases were men. Median time between TKI treatment initiation and T315I mutation detection was 29.2, 15.4, 5.8, and 9.1 months, respectively, for CP, AP, BP, and Ph(+) ALL patients. After T315I mutation detection, second-generation TKIs were used in 56% of cases, hydroxyurea in 39%, imatinib in 35%, cytarabine in 26%, MK-0457 in 11%, stem cell transplantation in 17%, and interferon-alpha in 6% of cases. Median overall survival from T315I mutation detection was 22.4, 28.4, 4.0, and 4.9 months, and median progression-free survival was 11.5, 22.2, 1.8, and 2.5 months, respectively, for CP, AP, BP, and Ph(+) ALL patients. These results confirm that survival of patients harboring a T315I mutation is dependent on disease phase at the time of mutation detection.
AB - The BCR-ABL T315I mutation represents a major mechanism of resistance to tyrosine kinase inhibitors (TKIs). The objectives of this retrospective observational study were to estimate overall and progression-free survival for chronic myeloid leukemia in chronic-phase (CP), accelerated-phase (AP), or blastic-phase (BP) and Philadelphia chromosome-positive (Ph)(+) acute lymphoblastic leukemia (ALL) patients with T315I mutation. Medical records of 222 patients from 9 countries were reviewed; data were analyzed using log-rank tests and Cox proportional hazard models. Median age at T315I mutation detection was 54 years; 57% cases were men. Median time between TKI treatment initiation and T315I mutation detection was 29.2, 15.4, 5.8, and 9.1 months, respectively, for CP, AP, BP, and Ph(+) ALL patients. After T315I mutation detection, second-generation TKIs were used in 56% of cases, hydroxyurea in 39%, imatinib in 35%, cytarabine in 26%, MK-0457 in 11%, stem cell transplantation in 17%, and interferon-alpha in 6% of cases. Median overall survival from T315I mutation detection was 22.4, 28.4, 4.0, and 4.9 months, and median progression-free survival was 11.5, 22.2, 1.8, and 2.5 months, respectively, for CP, AP, BP, and Ph(+) ALL patients. These results confirm that survival of patients harboring a T315I mutation is dependent on disease phase at the time of mutation detection.
U2 - 10.1182/blood-2009-04-219410
DO - 10.1182/blood-2009-04-219410
M3 - Journal article
C2 - 19843886
SN - 0006-4971
VL - 114
SP - 5271
EP - 5278
JO - Blood
JF - Blood
IS - 26
ER -